Aurgalys Team
Selected Customers
Interim Management
Quantum Genomics [ALQGC]
Corporate Finance
Management Assistance
Due Diligence
Interim Management
Investor Assistance
Onxeo [ONXEO]
Diaxonhit [ALEHT]

.:: Onxeo [ONXEO] ::.

Onxeo resulted from the merger of French BioAlliance Pharma and Danish Topotarget. Onxeo is dedicated to the development of orphan drug in oncology.

As of March 24th, 2015, there are 3 advanced products in Onxeo’s pipeline:

  • Beleodaq, approved on July 3rd, 2014 by the FDA for the treatment of relapse/refractory Peripheral T-Cell Lymphoma. Partner Spectrum Pharmaceuticals generated $4.9M of sales with Beleodaq
  • Livatag, in phase III (40% patients recruited), for the treatment of primary liver cancer (Results in 2016/2017)
  • Validive, phase III-ready for the treatment of radiotherapy-induced oral mucositis in head and neck cancer. Positive preliminary results published October 30th, 2014

Onxeo has also successfully marketed one product in Europe and the US, Loramyc (oral candidiasis). Sitavig (oral herpes) obtained marketing approval in 10 European countries and was launched in the US by partner Innocutis in July 2014.

We initiated BioAlliance’s coverage in 2009 and have conducted regular analyses since then. We are now publishing our reports under the company name Onxeo. These analyst reports are freely available for download on the links below.